==== Front J Exp Clin Cancer Res J Exp Clin Cancer Res Journal of Experimental & Clinical Cancer Research : CR 0392-9078 1756-9966 BioMed Central London 1749 10.1186/s13046-020-01749-x Review The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors Jia Xiao-Hui 1 Geng Lu-Ying 1 Jiang Pan-Pan 1 Xu Hong 1 Nan Ke-Jun 12 Yao Yu 1 Jiang Li-Li 1 Sun Hong 1 Qin Tian-Jie 1 http://orcid.org/0000-0003-0119-6087Guo Hui guohuihappy97@163.com 134 1 grid.452438.cDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi China 2 Oncology Hospital, Xi’an International Medical Center Hospital, Xi’an, Shaanxi China 3 grid.43169.390000 0001 0599 1243Key Laboratory of Environment and Genes Related to Diseases, Xi’an Jiaotong University, Ministry of Education of China, Xi’an, Shaanxi China 4 grid.452438.cTranslational Medicine Center, The First Affiliated Hospital of Xian Jiaotong University, Xi’an, Shaanxi China 14 12 2020 14 12 2020 2020 39 28418 8 2020 22 10 2020 © The Author(s) 2020Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.The enthusiasm for immune checkpoint inhibitors (ICIs), an efficient tumor treatment model different from traditional treatment, is based on their unprecedented antitumor effect, but the occurrence of immune-related adverse events (irAEs) is an obstacle to the prospect of ICI treatment. IrAEs are a discrete toxicity caused by the nonspecific activation of the immune system and can affect almost all tissues and organs. Currently, research on biomarkers mainly focuses on the gastrointestinal tract, endocrine system, skin and lung. Several potential hypotheses concentrate on the overactivation of the immune system, excessive release of inflammatory cytokines, elevated levels of pre-existing autoantibodies, and presence of common antigens between tumors and normal tissues. This review lists the current biomarkers that might predict irAEs and their possible mechanisms for both nonspecific and organ-specific biomarkers. However, the prediction of irAEs remains a major clinical challenge to screen and identify patients who are susceptible to irAEs and likely to benefit from ICIs. Supplementary Information Supplementary information accompanies this paper at 10.1186/s13046-020-01749-x. Targeted Therapy Fund of Chinese Society of Clinical OncologyY-sy2018-075 and Y-HR2015-139Guo Hui Outstanding Youth Project of Shaanxi Province2020JC-35Guo Hui http://dx.doi.org/10.13039/100007452Wu Jieping Medical Foundation320.6750.19094-51Guo Hui issue-copyright-statement© The Author(s) 2020 ==== Body Background In recent years, immune checkpoint inhibitors (ICIs) have achieved gratifying effects in a wide variety of tumors, including melanoma [1], renal cell carcinoma [2] and non-small cell lung cancer (NSCLC) [3], which greatly changed the traditional tumor treatment strategy and brought more survival benefits to patients [4, 5]. However, much of the enthusiasm for ICIs is based on long-term survival benefits, which occur in only a few patients. The survival benefit of patients is not only determined by the efficacy but also affected by adverse events. While ICIs represent a new field against cancer, they have also produced a unique set of immune-related adverse events (irAEs) that could have serious or even fatal consequences. Only by improving efficacy and reducing toxicity as much as possible could patient survival be improved. Undeniably, irAEs are very common, depending on the ICI mechanism. The application of ICIs destroys the mechanism that might protect tissues from autoimmune response damage [6], enhances the activity of T cells against antigens presented in tumors and healthy tissues [7], and increases the level of pre-existing autoantibodies and inflammatory factors [7], leading to a series of irAEs. However, current research on the mechanisms of irAEs is still in the early stage, and there are no recognized and universal mechanisms to explain irAEs. Strikingly, discrete toxicities caused by the nonspecific activation of the immune system could affect almost all tissues and organs. Among them, irAEs of the digestive system, endocrine organs and lungs are more common, and the heart, liver, kidneys, nerves, and eyes are relatively less affected [8]. The major fatal toxicities are cardiotoxicity, neurotoxicity and interstitial pneumonia, which are as high as 45% [9]. In some studies, the reported incidence was as high as 90% for any grade irAEs from ICI monotherapy [10]. A meta-analysis indicated an overall incidence over 70% with anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) monotherapy (ipilimumab, IPI) [11] and 27–78% in phase 3 trials of anti-programmed cell death protein 1 (anti-PD-1)/anti-programmed death ligand-1 (anti-PD-L1) agents [12–14]. Serious irAEs could lead to irreversible outcomes. The clinical characteristics of irAEs are relatively hidden with subtle imaging changes and are difficult to determine in the early stage. Therefore, some of the major clinical challenges include the early identification of patients who are susceptible to irAEs before they occur and the monitoring of the development of irAEs. Additionally, the common clinical strategy is mostly the combination of immunotherapy with chemotherapy or targeted therapy, so it is difficult to judge whether the adverse events are caused by immunotherapy alone, which suggests that it is important to accurately identify irAEs. Therefore, it is imperative to develop predictive markers for the occurrence of irAEs, to screen high-risk groups, to monitor the change in irAEs and to judge the outcome of irAEs to further optimize the benefit of patients and minimize the risk of toxicity. Many factors, such as sex and tumor type, might be able to predict the occurrence of irAEs. From extensive literature reports and clinical experience, it was found that males had a better response than females, but females were more likely to suffer irAEs [15]. Moreover, it is known that females are more susceptible to autoimmune diseases [16], which might be related to some sex-specific factors. In addition, a meta-analysis suggested that different tumor types had different immune microenvironments that might drive tissue-specific irAEs [17]. For example, dermatitis and arthritis were more common in melanoma patients than in renal cell carcinoma patients, while pneumonia and dyspnea were less common in melanoma patients [17]. However, these factors cannot accurately predict the occurrence of irAEs, making it difficult to achieve the purpose of early screening and early detection. Moreover, most of the previous studies focused on identifying immunotherapy advantage populations, and biomarkers of irAEs could help identify patients susceptible to severe irAEs as exclusion populations for immunotherapy. Therefore, considering the unique clinical value of biomarkers, as well as their convenience and accuracy, we listed the currently known predictive biomarkers of irAEs in this review to help better understand irAEs and provide clinical clues for subsequent studies. Methods Original articles on irAEs up to January 2020 were screened in Pubmed, Embase and Cochrane library. Medical Subject Headings are used to search for the terms carcinoma, immune checkpoint inhibitor and irAEs, including various adverse events. In this review, two investigators (JPP and XH) independently extracted data. Each study recorded the following information: biomarker, author, year, cancer type, patient number, treatment, correlation between biomarker and irAEs as well as possible hypothesis (Tables 1 and 2 for details). Each study was reviewed several times to ensure that no data was lost or mislabeled. If there are any objections, it was resolved through discussion or a third researcher to decide whether to include or not. For incomplete documents, try to contact the original author to supplement. The quality of included studies was assessed using the Cochrane Hand book 5.1.0 recommended risk of bias assessment tool. Including: (1) random allocation method; (2) allocation concealment; (3) whether to adopt a blind method for the participants and researchers; (4) whether the outcome was assessed by blind method; (5) completeness of outcome data; (6) Selective reporting of outcomes; (7) Other bias. The quality evaluation was conducted independently by two researchers. If there were different opinions, the decision was made through discussion or by referring to the viewpoint of the third researcher. Table 1 Nonspecific biomarker of irAEs Biomarker Author Year Cancer type Patient number Treatment Correlation between biomarker and irAEs Possible hypothesis CRP Abolhassani AR [18] 2019 MM 37 Anti-PD-1 Anti-CTLA-4 CRP elevation can predict the onset of irAEs in patients treated with ICIs in the absence of infectious disease. Tumor-promoting inflammation could cause a systemic inflammatory response;CRP level was positively associated with the infiltration of CD8 + T cell and Treg cell which could activate the systemic inflammatory response. IL-6 Okiyama N [19] 2017 MM 22 Anti-PD-1 The IL-6 level was significantly increased in the patients with psoriasiform dermatitis after nivolumab treatment. Overactivation of the immune system;Excessive release of inflammatory cytokines. Valpione S [15] 2018 MM 140 Anti-CTLA 4 A lower baseline level of IL-6 was strongly associated with the development of irAEs. Blood cell count Fujisawa Y [20] 2017 MM 101 Anti-PD-1 The increase of WBC counts and the decrease of relative lymphocyte counts were closely related to the incidence of grade 3–4 irAEs. Conventional blood cell counts could be a crude reflection of the body’s immune state, but the mechanism is unclear. Diehl A [21] 2017 Multiple solid tumors (lung cancer, MM, RCC, urothelial, HNSCC, Merkel cell carcinoma, colon cancer) 167 Anti-PD-1 Higher baseline and increase of absolute lymphocyte and eosinophil counts after ICIs treatment were strongly associated with the development of irAEs. Nakamura Y [22] 2019 MM 45 Anti-PD-1 The elevation of absolute eosinophil count at baseline and relative eosinophil count at 1 month might be valuable biomarkers to predicte endocrine irAEs. Cytokines Khan S [23] 2019 Multiple solid tumors (lung cancer, kidney cancer, MM, head/neck cancer, liver cancer, bladder cancer) 65 Anti-PD-1/L1 Anti-CTLA 4 The up-regulation of various cytokines after ICIs treatment was closely related to the occurrence of irAEs, especially the induced CXCL9, 10, 11 and 13. Activate T cell;Excessive release of cytokines;Various cytokines have powerful pro-inflammatory activities, including stimulating immune cell recruitment, proliferation, survival, differentiation, and effector functions, and many of these cytokines (such as IL-1A, IL-1B, IL-2, IFN 2, and IL-12P70) are associated with inflammation, which is the basis of autoimmune diseases. Lim SY [24] 2019 MM 98 Anti-PD-1 Anti-CTLA 4 Eleven cytokines, including G-CSF, GMCSF, Fractalkine, FGF-2, IFN-2, IL-12p70, IL-1a, IL-3 1B, IL-1RA, IL-2, IL-13, were significantly upregulated in patients with severe irAEs at baseline and early during treatment. TMB Bomze D [25] 2019 Multiple solid tumors 16,397 Anti-PD-1 There is a significant positive correlation between high TMB and irAEs during anti-PD-1 therapy in a variety of solid tumors While fighting against neoantigens, T cells could also cross-react with the corresponding wild-type antigens in normal tissues, resulting in damage to normal tissues. sCLTA-4 Pistillo MP [26] 2018 MM 113 Anti-CTLA-4 Higher baseline levels of sCTLA-4 were closely associated with irAEs, especially the gastrointestinal adverse events. Elevated levels of sCTLA-4 might block the interactions between full-length CTLA-4 expressed by autoreactive T cells and Tregs as well as B7 ligands, thus enhance the cytotoxicity of T cells and reduce the immunosuppression function of Treg cell. irAEs immune related adverse events, ICIs immune checkpoint inhibitors, CRP C reactive protein, MM malignant melanoma, Anti-PD-1/L1 anti-programmed cell death protein 1/ligand 1, Anti-CTLA-4 anti-cytotoxic T lymphocyte associated antigen-4, IL-6 interleukin 6, RCC renal cell carcinoma, HNSCC head and neck squamous cell carcinoma, WBC white blood cell, NLR neutrophil-lymphocyte ratio, TMB tumor mutation burden, sCLTA-4 soluble CTLA-4, flCTLA-4 full-length CTLA-4 Table 2 Organ-specific biomarker of irAEs irAEs Biomarker Author Year Cancer type Patient number Treatment Correlation between biomarker and irAEs Possible hypothesis GI The disorder of gut microbiome Chaput N [27] 2017 MM 26 Anti-CTLA-4 Baseline stool samples without bacteroidetes and with high levels of firmicutes were more likely to develop immune-related colitis. Impaired metabolism of beneficial bacteria;Decreased beneficial bacteria that inhibit inflammation;Microbial-derived products trigger an innate immune response. CD177 and CEACAM1 Shahabi V [28] 2013 MM 162 Anti-CTLA-4 CD177 and CEACAM1 were highly expressed at baseline and post-baseline in patients with GI irAEs. CD177 and CEACAM1, as activation markers of neutrophils, are involved in immune-mediated intestinal disease. Peripheral blood mRNA expression (CCL3, CCR3, IL-5, IL-8 and PTGS2) Friedlander P [8] 2018 MM 210 Anti-CTLA-4 Peripheral blood gene expression characteristics (mainly CCL3, CCR3, IL-5, IL-8 and PTGS2) were closely related to the immune-related diarrhea, especially grade 2–4 diarrhea. Up-regulated genes such as CCL3, CCR3, IL-5, IL-8 and PTGS2 are involved in inflammatory immune response. IL-17 Tarhini AA [29] 2015 MM 35 Anti-CTLA-4 Upregulation of IL-17 level at baseline and 6 weeks after ICIs treatment showed a noteworthy correlation with grade 3 diarrhea/colitis. IL-17, one of the up-regulated central inflammatory cytokines in IBD, was usually inhibited by CTLA-4, but the intervention of ICIs disrupted this ecological balance. HLA allele Hasan Ali O [30] 2019 NSCLC, MM 102 Anti-PD-1 Anti-CTLA-4 There was a significant correlation between HLA type II variant HLA-dqb1 * 03:01 and immune-related colitis. The presence of common antigens between the tumor and colon tissue causes misleading damage to the gastrointestinal tract by the immune system. Immune-related pneumonia CD74 Tahir SA [31] 2019 Bladder cancer, prostate cancer 8 Anti-CTLA-4 + Anti-PD-1 The increase of autoantibody CD74 level after ICIs treatment was notably correlated with immune-related pneumonia CD74 stimulates the release of inflammatory mediators;There is a common antigen between the tumor and lung; ICIs disrupts the mechanism that inhibits the inflammatory response of Th2 cells. Endocrine disorder Preexisting abnormal antibodies Toi Y [32] 2019 NSCLC 137 Anti-PD-1 Preexisting abnormal antibodies was independently associated with irAEs. Patients with positive RF are more likely to develop dermal irAEs, and thyroid dysfunction is more common in patients with positive antithyroid antibody. T-cells enhance the effect of PD-1 antibody, and might in turn induce B-cells to produce autoantibodies, which will lead to the toxic accumulation effect of pre-existing abnormal autoantibodies, and finally trigger irAEs. Thyroid dysfunction Abnormal TPOAb Gay S [33] 2019 NSCLC, MPM 28 Anti-CTLA-4 + Anti-PD-1 There was a association between widespread thyroid hypoechogenicity, decreased thyroid volume, elevated TPOAb after ICIs treatment and thyroid dysfunction. ICIs enhance T cell activity against antigens present in healthy tissues and increase pre-existing autoantibody levels. Hypophysitis GNAL and ITM2B Tahir SA [31] 2019 Prostate cancer, MM, RCC 9 ICI therapy Elevated levels of autoantibodies GNAL and ITM2B are closely related to the immune-related hypophysitis. The qualitative difference in the autoreactive effector T cells between anti-PD-1 / PD-L1 and anti-CTLA-4 treatment; The pituitary endocrine cells themselves might express CTLA-4, making hypophysis a direct target for anti-CTLA-4 antibodies. Dermatologic toxicity HLA alleles Hasan Ali O [30] 2019 NSCLC, MM 102 Anti-PD-1 Anti-CTLA-4 HLA- drb1 *11:01 was observably related with itching. The presence of common antigens between the tumor and skin causes dermatologic misleading damage. IL-17 Johnson D [34] 2019 MM 3 Anti-PD-1 Psoriasiform dermatologic toxicity induced by PD-1 inhibitor subsided after treatment with systemic interleukin-IL17A blockade. ICIs enhance the Th17-mediated immune response in susceptible patients. irAEs immune related adverse events, GI gastrointestinal irAEs, MM malignant melanoma, Anti-CTLA-4 anti-cytotoxic T lymphocyte associated antigen-4, Anti-PD-1/L1 anti-programmed cell death protein 1/ligand 1, IL-8 interleukin 8, IBD inflammatory bowel disease, HLA human leukocyte antigen, IL-17 interleukin 17, NSCLC non-small cell lung cancer, MPM malignant pleural mesothelioma, RCC renal cell carcinoma, ICI immune checkpoint inhibitor Potential biomarkers associated with irAEs IrAEs could be found in all organs, and its forms are also varied between target organs and ICIs. Based on the current data, several potential biomarkers have been identified to predict irAEs, as described below. Nonspecific biomarkers In cases of nonspecific symptoms such as fever, cough, and fatigue, it is often difficult to make timely and rapid clinical decisions due to complex screening imaging diagnosis or hematological examination because these are time consuming and require cautious differential diagnosis. Therefore, there is an urgent need to develop easily detectable biomarkers to identify nonspecific irAEs. The known nonspecific biomarkers of irAEs are shown in Table 1, and the possible mechanisms are shown in Fig. 1. Additionally, the quality assessment of the included studies is shown in supplementary Figure 1. Fig. 1 Possible mechanisms of nonspecific biomarkers of irAEs. a Possible mechanisms of CRP, IL-6 and blood cell count. Tumor-promoting inflammation can cause overactivation of the immune system and trigger a systemic inflammatory response, leading to some non-specific irAEs. b Possible mechanisms of cytokines. CXCL9/10/11, involved in the establishment of CXCL9/10/11-CXCR3 axis in tumor microenvironment, is chemokine to activate T cells and regulate the differentiation, activation and migration of immune cells. CXCL 13 is the B-cell chemoattractant. Their upregulation is associated with a variety of autoimmune diseases, which is considered to be a key cytokine axis closely related to irAEs. And the increased expression of 11 cytokines represented by CSF, fractalkine, and IL family is closely related to severe irAEs. c Possible mechanisms of TMB. Dead tumor cells can released neoantigens which produce a high TMB. While fighting against neoantigens, T cells could also cross-react with the corresponding wild-type antigens in normal tissues, resulting in damage to normal tissues. d Possible mechanisms of sCTLA-4. Elevated levels of sCTLA-4 might block the interactions between full-length CTLA-4 expressed by autoreactive T cells and Tregs as well as B7 ligands, thus enhance the cytotoxicity of T cells and reduce the immunosuppression function of Treg cell. PD-1/L1, programmed cell death protein 1/ligand 1; TIME, tumor immune microenvironment; IL-6, interleukin 6; CRP, C reactive protein; Th cell, helper T cell; CSF, colony stimulating factor; TMB, tumor mutation burden; CTLA-4, cytotoxic T lymphocyte associated antigen-4; sCTLA-4, soluble cytotoxic T lymphocyte associated antigen-4 C-reactive protein The theory that high C-reactive protein (CRP) levels are closely associated with poor prognosis is well known [35], and the current research focus has gradually shifted to the relationship between CRP levels and irAEs. A retrospective study found that CRP was increased in patients with irAEs, such as pituitary inflammation, hepatitis, thyroiditis and autoimmune colitis (upper limit of normal (ULN) 5 mg/L), but elevated CRP levels did not correlate with the severity of organ damage [18]. However, this hypothesis still needs to be verified by a larger patient cohort. Currently, the mechanism of the correlation between CRP and irAEs is unclear. CRP, as a representative acute phase reactant, is part of the nonspecific immune mechanism that reflects the presence of systemic inflammation in the host [18] and represents a high level of immunogenicity and tumor burden. Inflammatory cells could be attracted to sites of neoplasia and may promote cancer cells [36–38] which is a typical example of tumor cells conscripting normal cells to enhan ce tumor growth potential. This tumor-promoting inflammation is an important means to acquire the necessary capabilities for tumor cells [39], which is considered to indicate poor prognosis in many tumors [40, 41]. Additionally, some studies have shown that the elevation in CRP baseline levels was positively associated with the infiltration of CD8+ T cells and regulatory T (Treg) cells [41], and highly activated effector T cells could activate the systemic inflammatory response, which might be associated with nonspecific irAEs [42] (Fig. 1a). CRP as a biomarker has the advantages of easy sample collection, simple measurement and convenient analysis. However, the CRP level is susceptible to a variety of physiological and pathological factors, such as acute or chronic infections, anti-infective and anti-inflammatory drugs and autoimmune diseases, which suggests that a single estimation of the CRP level is not able to accurately and objectively predict irAEs. Therefore, in short, patients were considered to suffer from irAEs if their CRP increased at least twice during the two-week interval, the procalcitonin level was low, and there was no evidence of infection (negative for etiological culture and serology) [18]. Interleukin − 6 Similar to the association with poor ICI efficacy [42, 43], an important observation was that a high interleukin-6 (IL-6) level after ICI treatment was closely related to irAEs, such as Crohn’s disease [44] and psoriasiform dermatitis [19]. In contrast, a previous study of malignant melanoma patients using a CTLA-4 inhibitor found that a lower baseline level of IL-6 was strongly associated with the development of irAEs [15], including colitis [27]. These results indicated that both low baseline IL-6 levels and increased IL-6 levels after ICI treatment might predict the occurrence of irAEs. This might be explained by the important role of IL-6 in inflammation. IL-6 has a two-sided effect on the development of tumors, both preventing tumor formation and promoting tumor progression [42, 45]. IL-6 plays an active role in innate and adaptive immunity, such as the activation of helper T (Th) cells, inhibition of Treg cells, and differentiation of B cells [46], and these overactive manifestations of the immune system are closely related to irAEs [7]. Another important deduction is the excessive release of inflammatory cytokines [7]. IL-6 plays an important role in the tumor-related systemic inflammatory response, not only as a major inducer of CRP [47] but also as a direct inducer of anti-inflammatory molecules [48], which are also considered potential mechanisms by which IL-6 participates in the occurrence of irAEs. The overall hypothesis is shown in Fig. 1a. However, so far, there is no consensus. Meanwhile, recent studies have shown that the CRP level in peripheral blood might act as a surrogate for IL-6 activity in vivo based on cytokine release syndrome (CRS) after treatment with chimeric antigen receptor T-cells (CAR-T cells) in leukemia [49]. A significant proportion of patients with irAEs had characteristics similar to those of patients with CRS [6], and IL-6 was significantly increased in CRS [49, 50], which directly demonstrated the effectiveness of IL-6 as an irAE biomarker. Blood cell count Blood counts have received widespread attention as a highly available specimen and a signal of irAEs. Fujisawa Y et al., by analyzing the fluctuation of blood counts on or before the day of irAEs in melanoma patients treated with nivolumab, found that the increase in white blood cell counts and the decrease in relative lymphocyte counts were closely related to the incidence of grade 3–4 irAEs, especially pulmonary irAEs [20]. A previous analysis suggested that a higher baseline and increase in absolute lymphocyte counts (ALC) and absolute eosinophil counts (AEC) after ICI treatment were strongly associated with the development of irAEs in patients with solid tumors (including lung cancer, kidney cancer, melanoma, etc.) treated with anti-PD-1 antibodies (baseline ALC > 2000, AEC ≥ 100) [21]. Encouragingly, studies by Nakamura Y et al. in melanoma patients treated with anti-PD-1 antibody showed that AEC > 240/μL at baseline and relative eosinophil count at 1 month > 3.2% could be valuable biomarkers for predicting endocrine irAEs [22]. Conversely, a study by Leila Khoja et al. revealed that in melanoma patients treated with IPI, the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and eosinophil-lymphocyte ratio (ELR) were not associated with toxicity but only with the response to ICI treatment [51]. The reason for this paradox might be the difference in pathological changes caused by different types of ICIs. Conventional blood cell counts are known to be a crude reflection of the body’s immune state and are crucial in classic cellular, humoral, and tumor immunity (Fig. 1a). However, considering the involvement of different types of ICIs and various affected sites, the mechanism is complex and diverse, and no unified conclusion has been reached yet. Moreover, the blood cell count has certain limitations as a biomarker. Similar to CRP, it is primarily affected by the patient’s inflammatory state, physical condition, recent new infections or other diseases unrelated to the original tumor and to a large extent by myelosuppression due to chemotherapy or radiotherapy. Therefore, the accuracy and reliability of blood cell count as a predictor of irAEs still need to be further weighed and verified. Cytokines Cytokines, a kind of small-molecule protein with extensive biological activities, play a crucial role in a variety of life activities, such as innate and adaptive immunity, tumor growth, and the inflammatory response [52]. Among the 40 cytokines/chemokines assessed in plasma, Shaheen Khan et al. found that compared with the baseline level before ICI treatment, the upregulation of various cytokines after ICI treatment, especially induced CXCL9, 10, 11 and 13, was closely related to the occurrence of irAEs [23]. CXCL9/10/11, involved in the establishment of the CXCL9/10/11-CXCR3 axis in the tumor microenvironment, is a chemokine that activates T cells [23], which could regulate the differentiation, activation and migration of immune cells and effectively inhibit tumor growth [53] (Fig. 1b). Moreover, previous studies indicated that they were associated with a variety of autoimmune diseases, including thyroiditis, inflammatory bowel disease (IBD), and systemic sclerosis [52, 54]. Therefore, it is considered to be a key cytokine axis closely related to irAEs, but as yet, it has not been observed to be associated with organ-specific irAEs. CXCL 13, as a B-cell chemoattractant, is mainly expressed in mature B-cells, CD4+ follicular Th cells and activated Treg cells [54, 55] and participates in a series of autoimmune and inflammatory diseases, including multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus [56–59] (Fig. 1b). At the same time, the levels of IL-6, CXCL2, CCL20, CXCL8 and CCL23 in patients with irAEs were also significantly higher than in those without irAEs [23]. Therefore, this might support the hypothesis that ICI treatment induced an excessive immune storm that ultimately led to irAEs. Furthermore, in another retrospective study, the elevation of cytokines was found prior to ICI treatment [60], which might be in favor of the assumption that ICI treatment triggered a silent subclinical inflammatory response. Remarkably, the complex tumor microenvironment is a critical regulator involved in immune escape, progression, and distant metastasis [61]. High expression of hepatocyte growth factor and colony-stimulating factor-1 (CSF-1) has also been found to promote immune tolerance in the immunosuppressive microenvironment of hepatocellular carcinoma as an inflammation-associated tumor [62]. Interestingly, the study of Lim SY et al. also confirmed that the increased expression of 11 cytokines represented by the CSF, fractalkine, and IL families is closely related to severe irAEs [24]. These cytokines not only have strong pro-inflammatory activity but also participate in the inflammation of various autoimmune diseases [63, 64], so they could predict irAEs to a certain extent. In summary, cytokines are a potential biomarker for predicting irAEs, but no organ specificity has been found. Tumor mutation burden Tumor mutation burden (TMB) has been widely promoted as a useful biomarker for predicting the expected therapeutic response of tumors treated with immunotherapy. Then, a challenging question arises: does TMB have the same predictive power for irAEs? A large retrospective analysis of 16,411,749 irAE reports from 5,160,064 patients by David Bomze et al. revealed a significant positive correlation between high TMB and irAEs during anti-PD-1 therapy in a variety of solid tumors [25]. One contributing mechanism is the antigen spreading theory (Fig. 1c). After ICIs are taken, tumor cells die and release antigens, including neoantigens, which results in high TMB [25]. While fighting against neoantigens, T cells could also cross-react with the corresponding wild-type antigens in normal tissues [65], resulting in damage to normal tissues. The association between high TMB and irAEs was via the release of potential neoantigens, which is consistent with the theory of a positive correlation between high TMB and improved response to anti-PD-1 therapy. Regrettably, however, no studies have shown a link between TMB and organ-specific irAEs or their severity. There is currently no evidence linking TMB to irAEs caused by other ICIs, such as PD-L1 and CTLA-4 inhibitors. These valuable clinical questions are expected to be addressed by further research. In conclusion, high TMB might be a potential biomarker for assessing the risk of irAEs in vulnerable patient groups, but it needs to be validated and further explored in large prospective clinical studies. sCLTA-4 level Maria Pia Pistillo et al. suggested that higher baseline levels of soluble CTLA-4 (sCTLA-4 > 200 pg/ml) were closely associated with irAEs in melanoma patients treated with IPI, especially gastrointestinal irAEs [26]. One possible hypothesis is based on the dysregulation of autoreactive T cells (Fig. 1d). IPI exerts a powerful antitumor effect by blocking CTLA-4 binding to CD80 and CD86 ligands on antigen-presenting cells, which leads to T cell activation, intracellular congestion, and tumor-specific effects [66, 67]. Maria Pia Pistillo and colleagues suggested that elevated sCTLA-4 levels might block the interactions between full-length CTLA-4 expressed by autoreactive T cells and Tregs as well as B7 ligands, thus enhancing the cytotoxicity of T cells and reducing the immunosuppressive function of Treg cells [26]. In other words, a high level of sCTLA-4 reflects the increase in T cell activation after IPI treatment. In addition, as some previous studies have shown, an increase in sCTLA-4 levels was associated with longer overall survival (OS) in a variety of tumors, such as malignant melanoma [26], malignant mesothelioma [68], and NSCLC [69]. Moreover, many studies pointed out that the occurrence of irAEs was positively correlated with a better efficacy of ICIs [42, 70], which also supported that sCTLA-4 might be a promising biomarker for predicting irAEs. However, sCTLA-4 is mainly produced by Treg cells, which are mainly involved in immune escape, and some tumor cells can also produce and release sCTLA-4 into the blood [71]. Therefore, to some extent, a high level of sCTLA-4 could also be used as a marker of tumor immune escape and high tumor burden, which is contradictory to the above theory. Overall, the specific mechanism of sCTLA-4 as a biomarker for predicting irAEs and the association between sCTLA-4 levels and irAE grades still need further exploration. Organ-specific biomarkers Not all patients taking ICI treatment will suffer the same irAEs. Real world results have shown a variety of complex conditions, such as organ specificity and drug specificity, which might be influenced by the individual differences of patients, disease characteristics, drug types, regional culture and other mixed factors. Organ-specific irAEs are mainly a discrete toxicity caused by the nonspecific activation of the immune system, which could invade many organs, such as the gastrointestinal tract, endocrine system, and lungs. Different organs have different responses and affinities to ICI treatment. For example, colitis mostly occurs in patients taking IPI, while pneumonitis mostly occurs in patients taking anti-PD-1/PD-L1 [9]. What are the mechanisms of organ-specific irAEs? To date, no consensus has been reached. The hypotheses focus on the excessive release of inflammatory cytokines, overactivation of the immune system, amplification of preexisting abnormal antibodies, and misleading damage caused by the presence of common antigens between tumors and normal tissues. The organ-specific biomarkers of irAEs are shown in Table 2, and the possible mechanisms are shown in Fig. 2. The quality assessment of the included studies is shown in supplementary Figure 2. Fig. 2 Possible mechanisms of organ-specific biomarkers of irAEs. a Possible mechanisms of biomarkers associated with gastrointestinal irAEs. The main biomarkers for predicting gastrointestinal irAEs are disordered gut microbiome, CD177 and CEACAM1, peripheral blood mRNA expression (CCL3, CCR3, IL-5, IL-8 and PTGS2), IL-17 and HLA allele. a) One possible mechanism for disordered gut microbiome as a biomarker is that ICIs disrupt the stable microbial system in the gut, resulting in impaired metabolism of beneficial bacteria and a decrease in beneficial bacteria that inhibit inflammation. Another proposed hypothesis is that the microbial-derived products of intestinal disorders could trigger an in situ immune response that might eventually lead to the activation of self-reactive immune cells, causing local intestinal tissue damage. b) CD177 and CEACAM1 are involved in the activation of neutrophils and are thus closely related to immune-mediated intestinal diseases. c) Up-regulated genes such as CCL3, CCR3, IL-5, IL-8 and PTGS2 are involved in inflammatory immune response. d) IL-17, one of the up-regulated central inflammatory cytokines in IBD, was usually inhibited by CTLA-4, but the intervention of ICIs disrupted this ecological balance. e) HLA gene acts an important role in antigen expression and immune tolerance. The presence of common antigens between the tumor and colon tissue causes misleading damage to the gastrointestinal tract by the immune system. b Possible mechanisms of immune-related pneumonia. One possible hypothesis is that CD74 stimulates the release of inflammatory mediators. Additionally, there is a common antigen between the tumor and lung, causing misleading damage to the lung by the immune system. And another new hypothesis is ICIs disrupts the mechanism that inhibits the inflammatory response of Th2 cells. c Possible mechanisms of endocrine irAEs. a) Abnormal TPOAb might predict the thyroid dysfunction because ICIs enhance T cell activity against antigens present in healthy tissues and increase pre-existing autoantibody levels. b) Elevated levels of autoantibodies GNAL and ITM2B are closely related to the immune-related hypophysitis. Possible mechanism is anti-CTLA-4 could generate new reactive effector T cells in the pituitary, while anti-PD-1 / PD-L1 is more likely to make existing pituitary reactive effector T cells more active. Another hypothesis is that the pituitary endocrine cells themselves might express CTLA-4, making hypophysis a direct target for anti-CTLA-4 antibodies and causing hypophysis destruction. d Possible mechanisms of dermatologic toxicity. a) HLA gene mediates a variety of autoimmune diseases and the presence of common antigens between the tumor and skin causes dermatologic misleading damage. b) Th17 cells could induce the transcription of IL-17 cytokines. ICIs enhance the Th17-mediated immune response in susceptible patients, resulting in increased IL-17 levels and ultimately inducing dermatologic irAEs. IL-17, interleukin 17; NK cell, natural killer cell; ICIs, immune checkpoint inhibitors; Th cell, helper T cell; PD-1/L1/L2, programmed cell death protein 1/ligand 1/ligand 2; CTLA-4, cytotoxic T lymphocyte associated antigen-4; HLA, human leukocyte antigen Gastrointestinal irAEs Gastrointestinal (GI) irAEs, mainly manifested as diarrhea, colitis, and IBD, are the most common irAEs in ICI treatment [4, 72], especially IPI [73–75], and most occur in 2–3 cycles after ICI treatment [76]. In most cases, GI irAEs were tolerable and did not result in the termination of ICI treatment. However, when grade 2–4 diarrhea occurs, effective treatment measures should be taken promptly, and immunotherapy should be terminated if necessary [77]. The main mechanism is based on the hypothesis that ICI triggers the activation of T cells, which in turn leads to an excessive increase in a range of inflammatory cytokines. Currently, biomarkers for predicting GI irAEs are the focus of research. The main biomarkers are as follows, and the possible mechanisms are shown in Fig. 2a. The disorder of the gut microbiome It is well known that colitis is closely related to the decrease in the biodiversity of the intestinal microbiome [27] and the destruction of the host-bacterial ecosystem [78]. A clinical study by high-throughput sequencing of fecal samples from patients with advanced malignant melanoma treated with IPI showed that a significant reduction in the percentage of Firmicutes after immunotherapy, at least 2 times lower than baseline, was associated with immune-related colitis [27]. Intriguingly, the microbiota of patients prone to colitis was rich in Firmicutes at baseline but significantly decreased after ICI treatment, while a higher proportion of Bacteroidetes was present in patients without colitis. However, another study claimed that Bacteroidetes were underrepresented in metastatic melanoma patients with immune-related colitis treated with IPI [79]. Therefore, in short, patients with baseline stool samples without Bacteroidetes and with high levels of Firmicutes were more likely to develop immune-related colitis. A stable microbial system in the gut is essential for maintaining the intestinal epithelial barrier and anti-inflammatory effects [80], and its disruption leads to impairments in the bacterial polyamine transport system and biosynthesis of thiamine, riboflavin and pantothenate [79], which might be a potential hypothesis. Bacteroidetes can inhibit inflammation by stimulating Treg cell differentiation [81, 82], so patients lacking Bacteroidetes are more likely to experience a local intestinal inflammatory response. Another proposed mechanism is that the microbial-derived products of intestinal disorders could trigger an in situ immune response that might eventually lead to the activation of self-reactive immune cells [83], causing local intestinal tissue damage. CD177 and CEACAM1 Vafa Shahabi et al. analyzed the gene expression profiles of whole blood samples of melanoma patients treated with IPI and found that the neutrophil activation markers CD177 and CEACAM1 were highly expressed at baseline and postbaseline in patients with GI irAEs [28]. Moreover, the increase in CD177 occurred prior to the absolute neutrophil count increase in peripheral blood [28], indicating that CD177 might be a more sensitive early biomarker. The nonnegligible role of neutrophils in maintaining intestinal balance might support a reasonable hypothesis. CEACAM1 mediates activated neutrophils and other immune cells to adhere to endothelial cells [84, 85] involved in the pathogenesis of immune-mediated intestinal diseases. This could be verified in the colon biopsies of patients with GI irAEs, which revealed focal neutrophilic crypts and neutrophil infiltration in the lamina propria of the affected tissue [28, 86], the most prominent features of active colitis [28, 86]. This pathological change conforms to the theory of autoinflammation; that is, the local tissue inflammation of the host at the anatomical site leads to injury of the target organ [87]. In brief, increases in CD177 and CEACAM1 might be a signal for the occurrence of immune-related colitis. Peripheral blood mRNA expression (CCL3, CCR3, IL-5, IL-8 and PTGS2) A retrospective study based on two large clinical trials suggested that peripheral blood gene expression, mainly CCL3, CCR3, IL-5, IL-8 and PTGS2, which are involved in the inflammatory immune response, was closely related to immune-related diarrhea, especially grade 2–4 diarrhea [8]. In addition, previous studies have linked IL-8, CCR3, and CCL3 to diarrhea cases [88–90]. Furthermore, IL-8 expression is regulated by IL-17 [91], a cytokine clearly associated with the development of severe diarrhea/colitis [29]. This further increased the credibility of IL-8 as an irAE biomarker. IL-17 and human leukocyte antigen allele Ahmad A. Tarhini et al. reported that upregulation of IL-17 levels at baseline and 6 weeks after ICI treatment showed a noteworthy correlation with grade 3 diarrhea/colitis in melanoma patients treated with IPI [29]. IL-17 is a cytokine with a variety of inflammatory effects including the aggregation of neutrophils [92] and is one of the upregulated central inflammatory cytokines in IBD [93]. The increase in circulating IL-17 levels, which are usually inhibited by CTLA-4, might be a reflection of patients with subclinical colitis, but ICI intervention disrupts this ecological balance [92]. The inflammatory immune response might be the theoretical basis supporting IL-17 as a biomarker. In general, IL-17 might be developed as a promising biomarker to predict immune-related colitis due to its simple sample acquisition and easy detection. Additionally, Omar Hasan Ali et al. identified a significant correlation between the human leukocyte antigen (HLA) type II variant HLA-dqb1 * 03:01 and immune-related colitis through the analysis of HLA allele typing [30]. The HLA gene plays a central role in antigen expression and immune tolerance [83]. Currently, the possible mechanism lies in the presence of common antigens between tumors and colon tissues, which enables colon tissues to be recognized by antigen-specific T cells, thus causing colon damage [30]. Immune-related pneumonia Immune-related pneumonia is a change similar to interstitial pneumonia that is severe enough to be life-threatening [94]. Its clinical manifestations are complex and varied, and it is difficult to diagnose early and to distinguish from other pneumonia on imaging. Salahaldin A. Tahir et al. reported that the increase in an autoantibody against CD74 after ICI treatment was notably correlated with immune-related pneumonia, which suggested that CD74 plays an important role [31]. CD74, an autoantibody active protein, is an intracellular chaperone of MHC-II but is expressed on the cell membrane of immune cells, including macrophages [31] and could stimulate the release of inflammatory mediators [95]. Moreover, there was evidence that the presence of common antigens between tumor cells and lung tissues could enhance the recognition of lung antigens by specific T-cells [96], thus causing misleading damage to the lungs by the immune system. Alternatively, one new hypothesis was proposed that ICI disrupts the mechanism that inhibits the inflammatory response of Th2 cells in the body. Th2 cells participate in the development of pulmonary interstitial disease and the formation of eosinophils, and under normal circumstances, PD-1 interacts with PD-L2 to suppress the inflammatory response of Th2 cells, while ICI breaks this inhibition, thus producing immune-related pneumonia [97–101]. However, according to a study in children with severe viral pneumonia, CD74+ cells predominate in histopathological types with interstitial pneumonia as the pathological type [102], but no changes in CD74 have been observed in adults who developed pneumonia without immunotherapy. Therefore, it is reasonable to suspect that the change in CD74 level is specific to immune-associated pneumonia. In brief, the excessive release of inflammatory mediators, misleading damage due to the presence of common antigens between lung and tumor cells, and destruction of the inhibitory mechanism of the inflammatory response might be the causes of immune-related pneumonia (Fig. 2b). Endocrine disorder Preexisting abnormal antibodies Multivariate analysis was conducted on patients with irAEs after ICI treatment, and the presence of preexisting abnormal antibodies, such as rheumatoid factor (RF), antinuclear antibody, antithyroglobulin, and antithyroid peroxidase, was independently correlated with irAEs [32]. Patients with positive RF (RF > 15 IU/mL at pretreatment) were more likely to develop dermal adverse events, and thyroid dysfunction was more common in patients with positive antithyroid antibody, either antithyroglobulin or antithyroid peroxidase at pretreatment [32]. Interestingly, in patients with high PD-L1 expression, the frequency of any existing antibodies and rheumatoid factors was slightly higher, but no significant correlation was observed between antibody expression levels and the severity of irAEs [32]. Some evidence illustrated that patients with abnormal autoantibodies before treatment had a greater chance of producing antibodies [32]. PD-1 is highly expressed in activated B-cells, and B cells are also regulated by T-cell-independent and -dependent mechanisms [103, 104]. T-cells enhance the effect of PD-1 antibody and might in turn induce B-cells to produce autoantibodies, which will lead to the toxic accumulation effect of pre-existing abnormal autoantibodies and finally trigger irAEs [105, 106]. Abnormal TPOAb in thyroid dysfunction Endocrine toxicity is also a common irAE in immunotherapy. Up to 40% of patients have endocrine toxicity [107, 108], among which thyroid toxicity is the most common [109], mostly occurring 1–3 months after ICI treatment [109, 110]. Compared with CTLA-4 checkpoint inhibitors, PD-1 inhibitors are more prone to hypothyroidism, while compared with PD-L1 inhibitors, they might lead to the opposite conclusion: hyperthyroidism [111]. Stefano Gay et al. affirmed an interesting association between widespread thyroid hypoechogenicity, decreased thyroid volume, and elevated TPOAb after ICI treatment and thyroid dysfunction in patients with NSCLC or malignant pleural mesothelioma treated with ICIs [33]. This is consistent with the conclusion mentioned above that patients with positive anti-thyroid antibodies are more likely to develop thyroid dysfunction [32]. The decreased thyroid volume might be due to abnormal thyroid function. Additionally, hypoechoic grade and TPOAb elevation have been demonstrated to be a marker of the lymphocytic infiltration of thyroid parenchyma [112, 113]. This also corresponds with the hypothesis that ICIs enhance T cell activity against antigens present in healthy tissues [7] and increase pre-existing autoantibody levels [105, 106]. Anti-GNAL and anti-ITM2B in Hypophysitis Hypophysitis is an inflammatory disease of the pituitary gland. The main pathological change is that the pituitary gland is infiltrated by immune cells, resulting in the destruction of endocrine cells and the expansion or atrophy of the pituitary gland [114–116]. Pituitary inflammation was more likely to occur with CTLA-4 inhibitors than with PD-1/PD-L1 inhibitors [117]. Similar pathological changes were found in immune-related hypophysitis and autoimmune hypophysitis [118]. Salahaldin A. Tahir et al. took this as inspiration and identified that elevated levels of anti-GNAL and anti-ITM2B autoantibodies (a median of 1.7-fold and 2.5-fold increase for GNAL and ITM2B, respectively, compared to pretreatment samples) might contribute to immune-related hypophysitis by taking advantage of the large-scale screening of autoantibodies in plasma [31]. GNAL and ITM2B, as target proteins expressed in the pituitary gland epithelium, are established as key signal molecules in the normal secretion of various pituitary hormones, such as TRH [119, 120] and ACTH [121, 122], and the increase in anti-GNAL and anti-ITM2B autoantibodies is a manifestation of the destruction of pituitary function. Currently, the prevailing possible mechanism is the qualitative difference in autoreactive effector T cells between anti-PD-1/PD-L1 and anti-CTLA-4 treatment [123]. Anti-CTLA-4 could generate new pituitary reactive effector T cells by activating recent thymic emigrants to diversify the immune response [123], while anti-PD-1/PD-L1 is more likely to take effect in making existing pituitary reactive effector T cells more active by releasing pre-existing effector T cells [124]. Another hypothesis is that the pituitary endocrine cells themselves might express CTLA-4, making the hypophysis a direct target for anti-CTLA-4 antibodies and causing hypophysis destruction [125]. Furthermore, these results enlighten us that in addition to increased autoantibody levels, disorders of pituitary hormone levels regulated by GNAL and ITM2B, such as TRH and ACTH, as another sign of impaired pituitary function, might also become a promising new research direction to predict pituitary inflammation, but it is expected to be supported by theoretical studies in the future. Dermatologic toxicity HLA allele Derma-related adverse events mainly present as vitiligo [126, 127], rash and erythema [96], and cases of Stevens-Johnson syndrome and toxic epidermal necrosis are rarely reported [128]. As mentioned above, patients with preexisting abnormal RF are more likely to have derma-related adverse events after ICI treatment [9]. A retrospective study found that HLA-drb1 *11:01, a common genetic variant of HLA, was observably related to itching [30]. It is worth noting that dermatological irAEs have been demonstrated to imply universal activation of the immune system [129]. One proposed hypothesis is that there are potential shared antigens between tumor cells and normal tissue, such as skin, that could be recognized by antigen-specific T-cells, enhancing T cell recognition of skin antigens [96], and the HLA gene plays a vital role in antigen expression and immune tolerance [83], mediating a variety of autoimmune diseases [130]. IL-17 Daniel Johnson et al. reported a case of psoriasiform dermatologic toxicity in a melanoma patient that was induced by a PD-1 inhibitor and subsided after treatment with systemic IL-17A blockade [34]. Th17 cells can induce the transcription of IL-17 cytokines, which play a momentous role in a set of autoimmune diseases [131]. However, the blocking of CTLA-4 and PD-1 could increase the expression of Th17 cells in peripheral blood [132, 133]. Based on the crucial role of the Th17/IL17A axis in dermatologic diseases, such as psoriasis, it is hypothesized that ICIs enhance the Th17-mediated immune response in susceptible patients, thus causing some immune-related toxicities. Discussion Many biomarkers have been claimed to predict irAEs, but unfortunately, none is perfect. Currently, research on irAE biomarkers is still in its infancy, with little progress and some deficiencies. First, there is a clinical challenge that some biomarkers are not routine tests in clinical diagnosis and treatment, and the relatively high cost will severely limit their clinical application. Therefore, it is important to develop simple, measurable and accurate biomarkers for personalized patient management. Additionally, by reviewing the biomarkers that predicted irAEs, we found that little is known about the prediction of some fatal irAEs, such as cardiotoxicity, neurotoxicity, and hepatotoxicity. The reasons might be as follows: on the one hand, the incidence of fatal irAEs is low, which leads to a small sample size; on the other hand, the patients cannot cooperate well due to the high mortality and side effects of fatal irAEs. Therefore, these valuable clinical cases are of vital importance and need to be collected and analyzed carefully to solve this problem. Moreover, since the mechanisms of irAEs induced by ICIs are very complex and involve many factors, the discovery of new potential biomarkers will provide insights into the mechanisms of the early prediction and resolution of irAEs in clinical practice. Another key issue is the unicity of irAE treatment. Currently, corticosteroids remain the basis of treatment, and in severe cases, biological immunoregulatory drugs are needed [134]. However, high-dose corticosteroid therapy may bring long-term and potential adverse events to patients, leading to femoral head necrosis, electrolyte disturbance, aggravation of cardiovascular and cerebrovascular diseases, etc. The lack of individualized treatment might delay the effective control of irAEs, and thorough mechanistic research and translational research in the future might provide opportunities for new treatment methods. The well-researched pathogenesis of irAEs might provide more targeted interventions to reduce the systemic adverse reactions caused by hormone shock therapy. At present, some clinical studies attempt to combine some modulators of the immune microenvironment with immunotherapy to further improve the efficacy, such as the Keynote-037 study [135] and Keynote-252 study [136]. Therefore, the development of drugs to regulate the occurrence of irAEs may be a future research direction that is expected to provide new strategies for the precise treatment of irAEs. Many studies have shown that patients suffering from irAEs are more likely to achieve a longer survival benefit, which is a signal of lasting efficacy [70]. Therefore, could this correlation be used as evidence to support the deduction that biomarkers related to efficacy could also serve to predict the occurrence of irAEs? Indeed, there are some biomarkers that could predict not only the outcome of receiving ICI therapy but also the occurrence of irAEs. For example, the increase in IL-6 levels could also be used as a nonspecific biomarker to predict irAEs while being associated with poor treatment response [43]. The increased level of sCTLA-4 was applied to predict not only the good antitumor effect of anti-CTLA-4 but also the higher possibility of irAEs [26]. However, there are still some biomarkers, such as soluble PD-L1 (sPD-L1), that are only used to predict the efficacy of immunotherapy in current studies. Increased sPD-L1 levels are significantly linked with better treatment response in patients treated with anti-PD-1 therapy for NSCLC [137]. Conversely, in patients with multiple solid tumors taking PD-1/PD-L1, lower sPD-L1 levels were revealed to be associated with better treatment responses and survival outcomes [138, 139]. Therefore, this paradox still needs to be addressed by a larger cohort, but no relevant studies have yet shown a link between sPD-L1 and irAEs; the connection between them is expected to be revealed in the future. Future research could focus on the discovery of new and convenient markers for predicting the occurrence of irAEs. Moreover, it might also be a good direction to explore biomarkers that can simultaneously predict the reaction efficacy and the occurrence of irAEs, which has crucial clinical value. Admittedly, there are some limitations to this review. First, since most of the studies we included were retrospective studies, they may lead to certain selection bias and confounding bias. However, this limitation is mostly due to the lack of thorough studies and a series of randomized controlled trials to provide evidence. More prospective studies and further molecular mechanism exploration are expected to make up for this deficiency. In addition, some original literatures are excluded due to lack of sufficient credible evidence and complete experimental protocol and results presentation, which to some extent, may lead to incomplete retrieval of literature. Therefore, in order to understand the biomarkers associated with irAEs as comprehensively as possible, we strictly followed the retrieval strategy to review the literatures. Conclusion In conclusion, with the advent of the era of combined immunotherapy, the application scope and treatment population of immunotherapy are expanding. IrAEs, which affect multiple organs, have become a major obstacle to the application prospect of ICIs. The cautious management of irAEs, especially early detection and treatment, can facilitate achieving the maximum clinical benefit from immunotherapy. Extensive interdisciplinary cooperation to provide the best treatment options and the comprehensive consideration of multiple biomarkers to predict irAEs are also keys to the successful delivery of personalized treatment strategies. Additionally, irAEs can be used to screen and exclude people unsuitable for immunotherapy, which may provide another strategy for precise immunotherapy. Supplementary Information Additional file 1 : Supplementary Figure 1. The quality evaluation of studies related to non-specific biomarkers. Additional file 2 : Supplementary Figure 2. The quality evaluation of studies related to organ-specific biomarkers. Abbreviations ICIImmune checkpoint inhibitor NSCLCNon-small cell lung cancer irAEsImmune-related adverse events CTLA-4Cytotoxic T-lymphocyte antigen-4 IPIIpilimumab PD-1Programmed cell death protein 1 PD-L1Programmed cell death ligand-1 CRPC-Reactive protein ULNUpper limit of normal Treg cellT regulatory cells IL-6Interleukin − 6 ThHelper T cells CRSCytokine release syndrome CAR -T cellsChimeric antigen receptor T- cells ALCAbsolute lymphocyte counts AECAbsolute eosinophil counts NLRNeutrophil-lymphocytes ratio PLRPlatelets-lymphocytes ratio ELREosinophil-lymphocytes ratio IBDInflammatory bowel disease CSFColony-stimulating factor TMBTumor mutation burden sCTLA-4Soluble CTLA-4 OSOverall survival GIGastrointestinal irAEs HLAHuman leukocyte antigen RFRheumatoid factor Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Acknowledgements We are grateful to Dr. Si-Zhe Yu of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Jia Hou of the First Affiliated Hospital of Xi’an Jiaotong University for her valuable guidance on writing assistance and manuscript revision. Authors’ contributions XHJ and PPJ designed the study, performed literature searched and wrote the original manuscript. HX and LLJ conceived the project and prepared the figures and tables. LYG, HS and YY participated in the drafting and editing manuscript. TJQ and KJN revised the manuscript. HG revised the draft and final approved of the version to be submitted. All authors had full access to all data, critically revised the paper, approved the final analysis, and took responsibility for all aspects of the work to ensure that issues relating to the accuracy or integrity of any part of the work could be appropriately investigated and resolved. Funding This work was supported by Targeted Therapy Fund of Chinese Society of Clinical Oncology (Y-sy2018–075 and Y-HR2015–139), Outstanding Youth Project of Shaanxi Province (2020JC-35) and Wu Jieping Medical Foundation (320.6750.19094–51). Availability of data and materials No Applicable. Ethics approval and consent to participate No Applicable. Consent for publication No Applicable. Competing interests The authors declare no conflict of interest. ==== Refs References 1. Wolchok JD Chiarion-Sileni V Gonzalez R Rutkowski P Grob JJ Cowey CL Overall survival with combined nivolumab and ipilimumab in advanced melanoma N Engl J Med. 2017 377 14 1345 1356 10.1056/NEJMoa1709684 28889792 2. Rini BI Plimack ER Stus V Gafanov R Hawkins R Nosov D Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma N Engl J Med. 2019 380 12 1116 1127 10.1056/NEJMoa1816714 30779529 3. Paz-Ares L Luft A Vicente D Tafreshi A Gümüş M Mazières J Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer N Engl J Med. 2018 379 21 2040 2051 10.1056/NEJMoa1810865 30280635 4. Hoos A Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations Nat Rev Drug Discov. 2016 15 4 235 247 10.1038/nrd.2015.35 26965203 5. Papaioannou NE Beniata OV Vitsos P Tsitsilonis O Samara P Harnessing the immune system to improve cancer therapy Ann Transl Med. 2016 4 14 261 10.21037/atm.2016.04.01 27563648 6. Ke W Zhang L Dai Y The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs) Thorac Cancer. 2020 11 4 835 839 10.1111/1759-7714.13341 32043828 7. Postow MA Sidlow R Hellmann MD Immune-related adverse events associated with immune checkpoint blockade N Engl J Med. 2018 378 2 158 168 10.1056/NEJMra1703481 29320654 8. Friedlander P Wood K Wassmann K Christenfeld AM Bhardwaj N Oh WK A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab J Immunother Cancer. 2018 6 1 90 10.1186/s40425-018-0408-9 30227886 9. Wang DY Salem JE Cohen JV Chandra S Menzer C Ye F Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis JAMA Oncol. 2018 4 12 1721 1728 10.1001/jamaoncol.2018.3923 30242316 10. Elkrief A El Raichani L Richard C Messaoudene M Belkaid W Malo J Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors Oncoimmunology. 2019 8 4 e1568812 10.1080/2162402X.2019.1568812 30906663 11. Bertrand A Kostine M Barnetche T Truchetet ME Schaeverbeke T Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis BMC Med. 2015 13 undefined 211 10.1186/s12916-015-0455-8 26337719 12. Maughan BL Bailey E Gill DM Agarwal N Incidence of immune-related adverse events with program death receptor-1- and program death receptor-1 ligand-directed therapies in genitourinary cancers Front Oncol. 2017 7 undefined 56 28421161 13. Topalian SL Hodi FS Brahmer JR Gettinger SN Smith DC McDermott DF Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med. 2012 366 26 2443 2454 10.1056/NEJMoa1200690 22658127 14. Kumar V Chaudhary N Garg M Floudas CS Soni P Chandra AB Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy Front Pharmacol. 2017 8 undefined 49 10.3389/fphar.2017.00049 28228726 15. Valpione S Pasquali S Campana LG Piccin L Mocellin S Pigozzo J Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade J Transl Med. 2018 16 1 94 10.1186/s12967-018-1467-x 29642948 16. Schwinge D Schramm C Sex-related factors in autoimmune liver diseases Semin Immunopathol. 2019 41 2 165 175 10.1007/s00281-018-0715-8 30276446 17. Khoja L Day D Wei-Wu Chen T Siu LL Hansen AR Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review Ann Oncol. 2017 28 10 2377 2385 10.1093/annonc/mdx286 28945858 18. Abolhassani AR Schuler G Kirchberger MC Heinzerling L C-reactive protein as an early marker of immune-related adverse events J Cancer Res Clin Oncol. 2019 145 10 2625 2631 10.1007/s00432-019-03002-1 31492984 19. Okiyama N Tanaka R Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6 Nihon Rinsho Meneki Gakkai Kaishi. 2017 40 2 95 101 10.2177/jsci.40.95 28603207 20. Fujisawa Y Yoshino K Otsuka A Funakoshi T Fujimura T Yamamoto Y Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab J Dermatol Sci. 2017 88 2 225 231 10.1016/j.jdermsci.2017.07.007 28736218 21. Diehl A Yarchoan M Hopkins A Jaffee E Grossman SA Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors Oncotarget. 2017 8 69 114268 114280 10.18632/oncotarget.23217 29371985 22. Nakamura Y Tanaka R Maruyama H Ishitsuka Y Okiyama N Watanabe R Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies Jpn J Clin Oncol. 2019 49 5 431 437 10.1093/jjco/hyy201 30753621 23. Khan S Khan SA Luo X Fattah FJ Saltarski J Gloria-McCutchen Y Immune dysregulation in cancer patients developing immune-related adverse events Br J Cancer. 2019 120 1 63 68 10.1038/s41416-018-0155-1 30377338 24. Lim SY Lee JH Gide TN Menzies AM Guminski A Carlino MS Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy Clin Cancer Res. 2019 25 5 1557 1563 10.1158/1078-0432.CCR-18-2795 30409824 25. Bomze D Hasan Ali O Bate A Flatz L Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden JAMA Oncol. 2019 5 11 1633 1635 10.1001/jamaoncol.2019.3221 6707013 26. Pistillo MP Fontana V Morabito A Dozin B Laurent S Carosio R Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study Cancer Immunol Immunother 2019 68 1 97 107 10.1007/s00262-018-2258-1 30311027 27. Chaput N Lepage P Coutzac C Soularue E Le Roux K Monot C Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab Ann Oncol. 2017 28 6 1368 1379 10.1093/annonc/mdx108 28368458 28. Shahabi V Berman D Chasalow SD Wang L Tsuchihashi Z Hu B Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events J Transl Med. 2013 11 75 10.1186/1479-5876-11-75 23521917 29. Tarhini AA Zahoor H Lin Y Malhotra U Sander C Butterfield LH Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma J Immunother Cancer. 2015 3 39 10.1186/s40425-015-0081-1 26380086 30. Hasan Ali O Berner F Bomze D Fässler M Diem S Cozzio A Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors Eur J Cancer. 2019 107 8 14 10.1016/j.ejca.2018.11.009 30529903 31. Tahir SA Gao J Miura Y Blando J Tidwell RSS Zhao H Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities Proc Natl Acad Sci U S A. 2019 116 44 22246 22251 10.1073/pnas.1908079116 31611368 32. Toi Y Sugawara S Sugisaka J Ono H Kawashima Y Aiba T Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer JAMA Oncol. 2019 5 3 376 383 10.1001/jamaoncol.2018.5860 30589930 33. Gay S, Rossi G, Corica G, Graziani G, Genova C, Rijavec E, et al. RETRACTED ARTICLE: Can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label study. Endocrine. 2019; 10.1007/s12020-019-01854-8. 34. Johnson D Patel AB Uemura MI Trinh VA Jackson N Zobniw CM IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy Cancer Immunol Res. 2019 7 6 860 865 10.1158/2326-6066.CIR-18-0682 30996018 35. Heppt MV Heinzerling L Kähler KC Forschner A Kirchberger MC Loquai C Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition Eur J Cancer (Oxford, England: 1990) 2017 82 56 65 10.1016/j.ejca.2017.05.038 36. Coussens LM Raymond WW Bergers G Laig-Webster M Behrendtsen O Werb Z Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis Genes Dev. 1999 13 11 1382 1397 10.1101/gad.13.11.1382 10364156 37. Cordon-Cardo C Prives C At the crossroads of inflammation and tumorigenesis J Exp Med. 1999 190 10 1367 1370 10.1084/jem.190.10.1367 10562311 38. Hudson JD Shoaibi MA Maestro R Carnero A Hannon GJ Beach DH A proinflammatory cytokine inhibits p53 tumor suppressor activity J Exp Med. 1999 190 10 1375 1382 10.1084/jem.190.10.1375 10562313 39. Hanahan D Weinberg RA The hallmarks of cancer Cell. 2000 100 1 57 70 10.1016/S0092-8674(00)81683-9 10647931 40. Shrotriya S Walsh D Bennani-Baiti N Thomas S Lorton C C-Reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review PloS one. 2015 10 12 e0143080 10.1371/journal.pone.0143080 26717416 41. Nakayama T Saito K Kumagai J Nakajima Y Kijima T Yoshida S Higher serum C-reactive protein level represents the immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma Clin Genitourin Cancer. 2018 16 6 e1151 e1158 10.1016/j.clgc.2018.07.027 30213543 42. Weber JS Kahler KC Hauschild A Management of immune-related adverse events and kinetics of response with ipilimumab J Clin Oncol. 2012 30 21 2691 2697 10.1200/JCO.2012.41.6750 22614989 43. Hara M Nagasaki T Shiga K Takahashi H Takeyama H High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab Surg Today. 2017 47 4 483 489 10.1007/s00595-016-1404-7 27549777 44. Atreya R Mudter J Finotto S Müllberg J Jostock T Wirtz S Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo Nat Med. 2000 6 5 583 588 10.1038/75068 10802717 45. Colotta F Allavena P Sica A Garlanda C Mantovani A Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability Carcinogenesis. 2009 30 7 1073 1081 10.1093/carcin/bgp127 19468060 46. Scheller J Chalaris A Schmidt-Arras D Rose-John S The pro- and anti-inflammatory properties of the cytokine interleukin-6 Biochim Biophys Acta. 2011 1813 5 878 888 10.1016/j.bbamcr.2011.01.034 21296109 47. Asegaonkar SB Asegaonkar BN Takalkar UV Advani S Thorat AP C-Reactive protein and breast cancer: new insights from old molecule Int J Breast Cancer. 2015 2015 145647 10.1155/2015/145647 26693355 48. Kumari N Dwarakanath BS Das A Bhatt AN Role of interleukin-6 in cancer progression and therapeutic resistance Tumour Biol 2016 37 9 11553 11572 10.1007/s13277-016-5098-7 27260630 49. Lee DW Gardner R Porter DL Louis CU Ahmed N Jensen M Current concepts in the diagnosis and management of cytokine release syndrome Blood. 2014 124 2 188 195 10.1182/blood-2014-05-552729 24876563 50. Brudno JN Kochenderfer JN Toxicities of chimeric antigen receptor T cells: recognition and management Blood. 2016 127 26 3321 3330 10.1182/blood-2016-04-703751 27207799 51. Khoja L Atenafu EG Templeton A Qye Y Chappell MA Saibil S The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma Cancer Med. 2016 5 10 2792 2799 10.1002/cam4.878 27683208 52. Rotondi M Chiovato L Romagnani S Serio M Romagnani P Role of chemokines in endocrine autoimmune diseases Endocr Rev. 2007 28 5 492 520 10.1210/er.2006-0044 17475924 53. Tokunaga R Zhang W Naseem M Puccini A Berger MD Soni S CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy Cancer Treat Rev. 2018 63 undefined 40 47 10.1016/j.ctrv.2017.11.007 29207310 54. Magliozzi R Howell O Vora A Serafini B Nicholas R Puopolo M Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology Brain. 2007 130 null 1089 1104 17438020 55. Henneken M Dorner T Burmester GR Berek C Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus Arthritis Res Ther. 2005 7 5 R1001 R1013 10.1186/ar1776 16207316 56. Barone F Bombardieri M Rosado MM Morgan PR Challacombe SJ De Vita S CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization J Immunol. 2008 180 7 5130 5140 10.4049/jimmunol.180.7.5130 18354239 57. Armengol MP Cardoso-Schmidt CB Fernandez M Ferrer X Pujol-Borrell R Juan M Chemokines determine local lymphoneogenesis and a reduction of circulating CXCR4+ T and CCR7 B and T lymphocytes in thyroid autoimmune diseases J Immunol. 2003 170 12 6320 6328 10.4049/jimmunol.170.12.6320 12794165 58. Rioja I Hughes FJ Sharp CH Warnock LC Montgomery DS Akil M Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor Arthritis Rheum. 2008 58 8 2257 2267 10.1002/art.23667 18668547 59. Meraouna A Cizeron-Clairac G Panse RL Bismuth J Truffault F Tallaksen C The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis Blood. 2006 108 2 432 440 10.1182/blood-2005-06-2383 16543475 60. Yamazaki N Kiyohara Y Uhara H Iizuka H Uehara J Otsuka F Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma Cancer Sci. 2017 108 5 1022 1031 10.1111/cas.13226 28266140 61. Son B Lee S Youn H Kim E Kim W Youn B The role of tumor microenvironment in therapeutic resistance Oncotarget. 2017 8 3 3933 3945 10.18632/oncotarget.13907 27965469 62. Bertino G Demma S Ardiri A Proiti M Mangia A Gruttadauria S The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies Biomed Res Int. 2015 2015 731469 10.1155/2015/731469 25893197 63. Moudgil KD Choubey D Cytokines in autoimmunity: role in induction, regulation, and treatment J Interferon Cytokine Res. 2011 31 10 695 703 10.1089/jir.2011.0065 21942420 64. Santamaria P Cytokines and chemokines in autoimmune disease: an overview Adv Exp Med Biol. 2003 520 1 7 10.1007/978-1-4615-0171-8_1 12613569 65. Castle JC Kreiter S Diekmann J Löwer M van de Roemer N de Graaf J Exploiting the mutanome for tumor vaccination Cancer Res. 2012 72 5 108 191 10.1158/0008-5472.CAN-11-3722 66. Peggs KS Quezada SA Korman AJ Allison JP Principles and use of anti-CTLA4 antibody in human cancer immunotherapy Curr Opin Immunol. 2006 18 2 206 213 10.1016/j.coi.2006.01.011 16464564 67. Tarhini AA Edington H Butterfield LH Lin Y Shuai Y Tawbi H Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab PloS one. 2014 9 2 e87705 10.1371/journal.pone.0087705 24498358 68. Roncella S Laurent S Fontana V Ferro P Franceschini MC Salvi S CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor Cancer Immunol Immunother. 2016 65 8 909 917 10.1007/s00262-016-1844-3 27207606 69. Salvi S Fontana V Boccardo S Merlo DF Margallo E Laurent S Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer Cancer Immunol Immunother. 2012 61 9 1463 1472 10.1007/s00262-012-1211-y 22318401 70. Akamatsu H Murakami E Oyanagi J Shibaki R Kaki T Takase E Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer Oncologist. 2020 25 4 e679 e683 10.1634/theoncologist.2019-0299 32297443 71. Ward FJ Dahal LN Wijesekera SK Abdul-Jawad SK Kaewarpai T Xu H The soluble isoform of CTLA-4 as a regulator of T-cell responses Eur J Immunol. 2013 43 5 1274 1285 10.1002/eji.201242529 23400950 72. Beck KE Blansfield JA Tran KQ Feldman AL Hughes MS ROYAL RE Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 J Clin Oncol. 2006 24 15 2283 2289 10.1200/JCO.2005.04.5716 16710025 73. Robert C Long GV Brady B Dutriaux C Maio M Mortier L Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med. 2015 372 4 320 330 10.1056/NEJMoa1412082 25399552 74. Robert C Schachter J Long GV Arance A Grob JJ Mortier L Pembrolizumab versus Ipilimumab in Advanced Melanoma N Engl J Med. 2015 372 26 2521 2532 10.1056/NEJMoa1503093 25891173 75. Powles T Eder JP Fine GD Braiteh FS Loriot Y Cruz C MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature. 2014 515 7528 558 562 10.1038/nature13904 25428503 76. Berman D Parker SM Siegel J Chasalow SD Weber J Galbraith S Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma Cancer Immun. 2010 10 11 21090563 77. Michot JM Bigenwald C Champiat S Collins M Carbonnel F Postel-Vinay S Immune-related adverse events with immune checkpoint blockade: a comprehensive review Eur J Cancer 2016 54 139 148 10.1016/j.ejca.2015.11.016 26765102 78. Humphries A Daud A The gut microbiota and immune checkpoint inhibitors Hum Vaccin Immunotherapeutics. 2018 14 9 2178 2182 10.1080/21645515.2018.1442970 79. Dubin K Callahan MK Ren B Khanin R Viale A Ling L Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis Nat Commun. 2016 7 10391 10.1038/ncomms10391 26837003 80. Serriari NE Eoche M Lamotte L Lion J Fumery M Marcelo P Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases Clin Exp Immunol. 2014 176 2 266 274 10.1111/cei.12277 24450998 81. Round JL, Mazmanian SK. Inducible Foxp3 þ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci. 2010:12204–9 10.1073/pnas.0909122107. 82. Faith JJ Ahern PP Ridaura VK Cheng J Gordon JI Identifying gut microbe-host phenotype relationships using combinatorial communities in gnotobiotic mice Sci Transl Med. 2014 6 220 220ra211 10.1126/scitranslmed.3008051 83. Khan Z Hammer C Guardino E Chandler GS Albert ML Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach Genome Med. 2019 11 1 39 10.1186/s13073-019-0652-8 31221204 84. Gray-Owen SD Blumberg RS CEACAM1: contact-dependent control of immunity Nat Rev Immunol. 2006 6 6 433 446 10.1038/nri1864 16724098 85. Skubitz KM Skubitz AP Two new synthetic peptides from the N-domain of CEACAM1 (CD66a) stimulate neutrophil adhesion to endothelial cells Biopolymers. 2011 96 1 25 31 10.1002/bip.21447 20560140 86. Hamid O Schmidt H Nissan A Ridolfi L Aamdal S Hansson J A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma J Transl Med. 2011 9 204 10.1186/1479-5876-9-204 22123319 87. Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020; 10.1038/s41571-020-0352-8. 88. DuPont HL Ericsson CD Farthing MJ Gorbach S Pickering LK Rombo L Expert review of the evidence base for prevention of travelers' diarrhea J Travel Med. 2009 16 3 149 160 10.1111/j.1708-8305.2008.00299.x 19538575 89. Castor MG Rezende B Resende CB Alessandri AL Fagundes CT Sousa LP The CCL3/macrophage inflammatory protein-1alpha-binding protein evasin-1 protects from graft-versus-host disease but does not modify graft-versus-leukemia in mice J Immunol. 2010 184 5 2646 2654 10.4049/jimmunol.0902614 20100934 90. Song DJ Shim MH Lee N YOO Y CHOUNG JT CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis Allergy Asthma Immunol Res. 2017 9 4 360 367 10.4168/aair.2017.9.4.360 28497923 91. Nardinocchi L Sonego G Passarelli F Avitabile S Scarponi C Failla CM Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer Eur J Immunol. 2015 45 3 922 931 10.1002/eji.201445052 25487261 92. Nakamura Y Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events Front Med (Lausanne). 2019 6 119 10.3389/fmed.2019.00119 31192215 93. Abraham C Cho J Interleukin-23/Th17 pathways and inflammatory bowel disease Inflamm Bowel Dis. 2009 15 7 1090 1100 10.1002/ibd.20894 19253307 94. Tabchi S Messier C Blais N Immune-mediated respiratory adverse events of checkpoint inhibitors Curr Opin Oncol. 2016 28 4 269 277 10.1097/CCO.0000000000000291 27138570 95. Starlets D Gore Y Binsky I Haran M Harpaz N Shvidel L Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival Blood. 2006 107 12 4807 4816 10.1182/blood-2005-11-4334 16484589 96. Berner F Bomze D Diem S Ali OH Fässler M Ring S Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer JAMA Oncol. 2019 5 7 1043 1047 10.1001/jamaoncol.2019.0402 31021392 97. Lambrecht BN Hammad H The immunology of asthma Nat Immunol. 2015 16 1 45 56 10.1038/ni.3049 25521684 98. Bratke K Fritz L Nokodian F Geißler K Garbe K Lommatzsch M Differential regulation of PD-1 and its ligands in allergic asthma Clin Exp Allergy. 2017 47 11 1417 1425 10.1111/cea.13017 28865147 99. Chen DS Irving BA Hodi FS Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1 Clin Cancer Res. 2012 18 24 6580 6587 10.1158/1078-0432.CCR-12-1362 23087408 100. van der Werf N Redpath SA Azuma M Yagita H Taylor MD Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection PLoS Pathog. 2013 9 3 e1003215 10.1371/journal.ppat.1003215 23516361 101. Zhang Y Chung Y Bishop C Daugherty B Chute H Holst P Regulation of T cell activation and tolerance by PDL2 Proc Natl Acad Sci U S A. 2006 103 31 11695 11700 10.1073/pnas.0601347103 16864790 102. de Souza Costa VH Baurakiades E Viola Azevedo ML Traiano G Kowal Rosales J Kunze Larsen KS Immunohistochemistry analysis of pulmonary infiltrates in necropsy samples of children with non-pandemic lethal respiratory infections (RSV; ADV; PIV1; PIV2; PIV3; FLU A; FLU B) J Clin Virol. 2014 61 2 211 215 10.1016/j.jcv.2014.06.026 25052332 103. Nishimura H Nose M Hiai H Minato N Honjo T Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity. 1999 11 2 141 151 10.1016/S1074-7613(00)80089-8 10485649 104. Okazaki T Tanaka Y Nishio R Mitsuiye T Mizoguchi A Wang J Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice Nat Med. 2003 9 12 1477 1483 10.1038/nm955 14595408 105. Suzuki S Ishikawa N Konoeda F Seki N Fukushima S Takahashi K Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan Neurology. 2017 89 11 1127 1134 10.1212/WNL.0000000000004359 28821685 106. Williams TJ Benavides DR Patrice KA Dalmau JO de Ávila AL Le DT Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer JAMA Neurol. 2016 73 8 928 993 10.1001/jamaneurol.2016.1399 27271951 107. Scott ES Long GV Guminski A Clifton-Bligh RJ Menzies AM Tsang VH The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma Eur J Endocrinol. 2018 178 2 173 180 10.1530/EJE-17-0810 29187509 108. Iglesias P Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach Eur J Intern Med. 2018 47 6 13 10.1016/j.ejim.2017.08.019 28826822 109. Delivanis DA Gustafson MP Bornschlegl S Merten MM Kottschade L Withers S Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms J Clin Endocrinol Metab. 2017 102 8 2770 2780 10.1210/jc.2017-00448 28609832 110. de Filette J Jansen Y Schreuer M Everaert H Velkeniers B Neyns B Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab J Clin Endocrinol Metab. 2016 101 11 4431 4439 10.1210/jc.2016-2300 27571185 111. Barroso-Sousa R Barry WT Garrido-Castro AC Hodi FS Min L Krop IE Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis JAMA Oncol. 2018 4 2 173 182 10.1001/jamaoncol.2017.3064 28973656 112. Raber W Gessl A Nowotny P Vierhapper H Thyroid ultrasound versus antithyroid peroxidase antibody determination: a cohort study of four hundred fifty-one subjects Thyroid. 2002 12 8 725 731 10.1089/105072502760258712 12225642 113. Prummel MF Wiersinga WM Thyroid peroxidase autoantibodies in euthyroid subjects Best Pract Res Clin Endocrinol Metab. 2005 19 1 1 15 10.1016/j.beem.2004.11.003 15826919 114. Lupi I Zhang J Gutenberg A Landek-Salgado M Tzou SC MORI S From pituitary expansion to empty sella: disease progression in a mouse model of autoimmune hypophysitis Endocrinology. 2011 152 11 4190 4198 10.1210/en.2011-1004 21862619 115. Gutenberg A Buslei R Fahlbusch R Buchfelder M Brück W Immunopathology of primary hypophysitis: implications for pathogenesis Am J Surg Pathol. 2005 29 3 329 338 10.1097/01.pas.0000149707.12335.8e 15725801 116. Caturegli P Autoimmune hypophysitis: an underestimated disease in search of its autoantigen(s) J Clin Endocrinol Metab 2007 92 6 2038 2040 10.1210/jc.2007-0808 17554056 117. Faje A Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights Pituitary. 2016 19 1 82 92 10.1007/s11102-015-0671-4 26186958 118. Lin HH Gutenberg A Chen TY Tsai NM Lee CJ Cheng YC In situ activation of pituitary-infiltrating T lymphocytes in autoimmune hypophysitis Sci Rep. 2017 7 43492 10.1038/srep43492 28262761 119. Hashimoto K Zanger K Hollenberg AN Cohen LE Radovick S Wondisford FE cAMP response element-binding protein-binding protein mediates thyrotropin-releasing hormone signaling on thyrotropin subunit genes J Biol Chem. 2000 275 43 33365 33372 10.1074/jbc.M006819200 10931853 120. Peverelli E Mantovani G Lania AG Spada A cAMP in the pituitary: an old messenger for multiple signals J Mol Endocrinol. 2014 52 1 R67 R77 10.1530/JME-13-0172 24049068 121. Antoni FA Hunter EF Lowry PJ Noble JM Seckl JR Atriopeptin: an endogenous corticotropin-release inhibiting hormone Endocrinology. 1992 130 3 1753 1755 1311248 122. Kilger E Buehler A Woelfing H Kumar S Kaeser SA Nagarathinam A BRI2 protein regulates β-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE) J Biol Chem. 2011 286 43 37446 37457 10.1074/jbc.M111.288373 21873424 123. Kvistborg P Philips D Kelderman S Hageman L Ottensmeier C JOSEPH-PIETRAS D Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response Sci Transl Med. 2014 6 254 254ra128 10.1126/scitranslmed.3008918 25232180 124. Joshi MN Whitelaw BC Palomar MT Wu Y Carroll PV Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review Clin Endocrinol (Oxf). 2016 85 3 331 339 10.1111/cen.13063 26998595 125. Iwama S De Remigis A Callahan MK Slovin SF Wolchok JD Caturegli P Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody Sci Transl Med. 2014 6 230 230ra245 10.1126/scitranslmed.3008002 126. Robert C Ribas A Schachter J Arance A Grob JJ Mortier L Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Lancet Oncol. 2019 20 9 1239 1251 10.1016/S1470-2045(19)30388-2 31345627 127. Wolchok JD Neyns B Linette G Negrier S Lutzky J Thomas L Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol. 2010 11 2 155 164 10.1016/S1470-2045(09)70334-1 20004617 128. Weber JS Dummer R de Pril V Lebbe C Hodi FS Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma Cancer. 2013 119 9 1675 1682 10.1002/cncr.27969 23400564 129. Brahmer JR Lacchetti C Thompson JA Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary J Oncol Pract. 2018 14 4 247 249 10.1200/JOP.18.00005 29517954 130. Gutierrez-Arcelus M Rich SS Raychaudhuri S Autoimmune diseases - connecting risk alleles with molecular traits of the immune system Nat Rev Genet. 2016 17 3 160 174 10.1038/nrg.2015.33 26907721 131. Miossec P Korn T Kuchroo VK Interleukin-17 and type 17 helper T cells N Engl J Med. 2009 361 9 888 898 10.1056/NEJMra0707449 19710487 132. Dulos J Carven GJ van Boxtel SJ Evers S Driessen-Engels LJ Hobo W PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer J Immunother. 2012 35 2 169 178 10.1097/CJI.0b013e318247a4e7 22306905 133. von Euw E Chodon T Attar N Jalil J Koya RC Comin-Anduix B CTLA4 blockade increases Th17 cells in patients with metastatic melanoma J Transl Med. 2009 7 35 10.1186/1479-5876-7-35 19457253 134. Brahmer JR Lacchetti C Schneider BJ Atkins MB Brassil KJ Caterino JM Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol. 2018 36 17 1714 1768 10.1200/JCO.2017.77.6385 29442540 135. Long GV Dummer R Hamid O Gajewski TF Caglevic C Dalle S Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study Lancet Oncol. 2019 20 8 1083 1097 10.1016/S1470-2045(19)30274-8 31221619 136. Mitchell TC Hamid O Smith DC Bauer TM Wasser JS Olszanski AJ Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037) J Clin Oncol. 2018 36 32 3223 3230 10.1200/JCO.2018.78.9602 30265610 137. Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, et al. Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study. Cancers. 2020;12(2) 10.3390/cancers12020473. 138. Wang L Wang H Chen H Wang WD Chen XQ Geng QR Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma Oncotarget. 2015 6 38 41228 41236 10.18632/oncotarget.5682 26515600 139. Wei W Xu B Wang Y Wu C Jiang J Wu C Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: a meta-analysis Medicine. 2018 97 3 e9617 10.1097/MD.0000000000009617 29504990